In January 2024, Better Therapeutics, Inc submitted a request to the US Food and Drug Administration (FDA) for Breakthrough Device Designation for its new prescription digital therapeutic (PDT) designed to treat metabolic...
In January 2024, Better Therapeutics, Inc submitted a request to the US Food and Drug Administration (FDA) for Breakthrough Device Designation for its new prescription digital therapeutic (PDT) designed to treat metabolic...
In January 2024, Better Therapeutics Inc. and Glooko Inc. announced a partnership to integrate Better Therapeutics’ AspyreRx™ digital behavioral treatment for type 2 diabetes (T2D) into Glooko’s diabetes management platform.
In January 2024, Better Therapeutics Inc. and Glooko Inc. announced a partnership to integrate Better Therapeutics’ AspyreRx™ digital behavioral treatment for type 2 diabetes (T2D) into Glooko’s diabetes management platform.
In July 2023, GoodRx announced the launch of a new app known as Medicine Cabinet. In the press release, the company described the novel app as “a comprehensive solution designed to help consumers seamlessly manage their medications. Medicine...
In July 2023, GoodRx announced the launch of a new app known as Medicine Cabinet. In the press release, the company described the novel app as “a comprehensive solution designed to help consumers seamlessly manage their medications. Medicine...
Prescription digital therapeutics (PDTs) allow patients and prescribers to work collaboratively and to use ongoing technological advances to diagnose, treat, and manage various conditions effectively. Unfortunately, it appears that a lack of...
Prescription digital therapeutics (PDTs) allow patients and prescribers to work collaboratively and to use ongoing technological advances to diagnose, treat, and manage various conditions effectively. Unfortunately, it appears that a lack of...
Prescription digital therapeutics offer the potential to improve adherence and clinical outcomes while decreasing direct and indirect costs, addressing gaps in care, and enabling patients to take an active role in their care.
Prescription digital therapeutics offer the potential to improve adherence and clinical outcomes while decreasing direct and indirect costs, addressing gaps in care, and enabling patients to take an active role in their care.
As the number of PDTs continues to enter the market, it is important that clinicians and patients are aware of the regulatory processes instituted by the FDA to ensure the efficacy and safety of PDTs, and knowledge about the meticulous and...
As the number of PDTs continues to enter the market, it is important that clinicians and patients are aware of the regulatory processes instituted by the FDA to ensure the efficacy and safety of PDTs, and knowledge about the meticulous and...
Otsuka's Coverage Expectations Survey results regarding payer perspectives on prescription digital therapeutics (PDT) coverage revealed that payers recognize the potential value of PDTs while highlighting the need for clarity in FDA...
Otsuka's Coverage Expectations Survey results regarding payer perspectives on prescription digital therapeutics (PDT) coverage revealed that payers recognize the potential value of PDTs while highlighting the need for clarity in FDA...
PDTs have the potential to provide an additional tool to foster a patient-centered approach to managing diabetes while also making the patient an active partner in their day-to-day care, which in turn can improve glycemic control and reduce...
PDTs have the potential to provide an additional tool to foster a patient-centered approach to managing diabetes while also making the patient an active partner in their day-to-day care, which in turn can improve glycemic control and reduce...
While the number of prescription digital therapeutics (PDTs) continues to expand as possible treatments or adjunctive treatments for the management and prevention of various medical conditions, the degree of knowledge about the availability...
While the number of prescription digital therapeutics (PDTs) continues to expand as possible treatments or adjunctive treatments for the management and prevention of various medical conditions, the degree of knowledge about the availability...
As the number of prescription digital therapeutics (PDTs) expands, health care providers and patients are still largely unaware of their availability and potential benefits, highlighting the need for increased awareness and education...
As the number of prescription digital therapeutics (PDTs) expands, health care providers and patients are still largely unaware of their availability and potential benefits, highlighting the need for increased awareness and education...
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...